For patients in urgent need of PIK3CA inhibitors to control their condition, the emergence of the Lao Big Bear Pharmaceutical version of Alpelisib not only provides a specific purchasing channel beyond the expensive original drug, but also represents a tangible breakthrough in the affordability of life-saving medications.
What are the purchasing channels for Lao Big Bear version Alpelisib (50mg*28 tablets/box, 150mg*28 tablets/box)?
For specific purchasing methods, we recommend contacting professional customer service for detailed consultation.
Indications, Dosage, and Administration of Alpelisib
Indications
Alpelisib is a kinase inhibitor used in combination with fulvestrant for the treatment of specific patient populations whose disease has progressed following endocrine therapy. These patients must be postmenopausal women or men with breast cancer that is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and with a PIK3CA mutation confirmed by an FDA-approved test. The indication is for advanced or metastatic breast cancer.
Dosage and Administration
The recommended dosage of alpelisib is 300 mg (two 150 mg tablets) taken orally once daily with food to increase drug absorption. Tablets should be swallowed whole and not chewed, crushed, or split. Do not take tablets that are broken, cracked, or not intact. If a dose is missed, it can be taken with food within 9 hours after the usual time. If more than 9 hours have passed, skip the missed dose and take the next dose at the usual time the next day. If vomiting occurs after taking a dose, do not take an additional dose that day; resume the next dose at the usual time the next day. When used with Piqray, the recommended dosage of fulvestrant is 500 mg on days 1, 15, and 29, and once monthly thereafter. For adverse reactions, consider dose reduction, interruption, or permanent discontinuation of alpelisib.
Warnings and Precautions for Alpelisib
Before using the novel anticancer drug alpelisib, patients and healthcare providers must fully understand its potential serious adverse reactions and take appropriate preventive and management measures. The following are major warnings and precautions listed in the FDA-approved prescribing information:
1. Severe Hypersensitivity Reactions
Permanently discontinue alpelisib if severe hypersensitivity reactions occur and initiate appropriate symptomatic treatment immediately.
2. Severe Skin Reactions
Severe skin reactions including Stevens-Johnson syndrome (SJS) and erythema multiforme (EM) have been reported. Alpelisib is contraindicated in patients with a history of such reactions. Permanently discontinue if SJS, EM, or toxic epidermal necrolysis (TEN) is suspected.
3. Hyperglycemia
Severe hyperglycemia including ketoacidosis has been reported. The safety of Piqray in patients with type 1 or uncontrolled type 2 diabetes has not been established. Assess fasting plasma glucose (FPG) and HbA1c and optimize blood glucose before initiating treatment. Monitor periodically during treatment and initiate or optimize antihyperglycemic medication as needed.
4. Pneumonitis
Severe pneumonitis and interstitial lung disease have been reported. Monitor for clinical symptoms or radiographic changes. Interrupt or permanently discontinue alpelisib if severe pneumonitis occurs.
5. Diarrhea
Most patients experience diarrhea, including severe cases, which can lead to dehydration and acute kidney injury. Advise patients to start antidiarrheal treatment, increase oral fluids, and notify their healthcare provider immediately when diarrhea occurs. Interrupt, reduce dose, or discontinue alpelisib for severe diarrhea.
6. Embryo-Fetal Toxicity
Alpelisib can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for a period after the last dose.
